Media coverage about Ardelyx (NASDAQ:ARDX) has trended somewhat positive recently, according to Accern. Accern identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Ardelyx earned a news impact score of 0.12 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.0710207256689 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

These are some of the news stories that may have effected Accern’s analysis:

ARDX has been the subject of a number of recent analyst reports. Citigroup Inc. restated a “buy” rating and set a $12.00 target price (down previously from $17.00) on shares of Ardelyx in a report on Monday, May 15th. Zacks Investment Research upgraded Ardelyx from a “sell” rating to a “hold” rating in a report on Thursday, May 11th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $12.00 price objective (down previously from $19.00) on shares of Ardelyx in a report on Friday, May 19th. BidaskClub upgraded Ardelyx from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. Finally, BTIG Research reduced their price target on Ardelyx from $18.00 to $12.00 and set a “buy” rating for the company in a report on Tuesday, May 23rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $14.13.

Shares of Ardelyx (ARDX) traded up 5.15% on Friday, reaching $5.10. The company’s stock had a trading volume of 210,830 shares. The firm has a 50 day moving average price of $5.27 and a 200-day moving average price of $9.35. The stock’s market cap is $241.97 million. Ardelyx has a 12-month low of $4.05 and a 12-month high of $16.30.

Ardelyx (NASDAQ:ARDX) last released its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.09. Equities research analysts expect that Ardelyx will post ($2.18) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This story was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://theolympiareport.com/2017/08/12/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-ardelyx-ardx-stock-price-updated.html.

Ardelyx Company Profile

Ardelyx, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company’s products line includes cardiorenal portfolio and gastrointestinal portfolio.

Insider Buying and Selling by Quarter for Ardelyx (NASDAQ:ARDX)

Receive News & Ratings for Ardelyx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.